Human lung microvascular endothelial cells (HMVEC-L) angiogenic activity is inhibited by stable plasminogen activator inhibitor-1 (PAI-1) mutants via urokinase-dependent pathway Source: Annual Congress 2004 - Lung development and cancer Year: 2004
Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007
Plasminogen activator inhibitor-1 (PAI-1) mutations of extended half-life time inhibit angiogenic properties of human lung microvascular endothelial cells (HMVEC-L) Source: Eur Respir J 2003; 22: Suppl. 45, 225s Year: 2003
Regulation of plasminogen activator activity by inflammatory mediators in lung epithelial cells Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005
The mechanism of plasminogen activator inhibitor type-1 (PAI-1) Cys mutants inhibitory activity towards lung capillaries endothelial cells (HMVEC-L) Source: Eur Respir J 2005; 26: Suppl. 49, 93s Year: 2005
The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005
The effect of prostaglandin (PG) E2 and its receptor antagonists on urokinase-type plasminogen activator (uPA) production by human lung fibroblasts Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006
Influence of prostaglandin E2 on cell surface urokinase-type plasminogen activator expression and activity in lung adenocarcinoma cell line Source: Eur Respir J 2005; 26: Suppl. 49, 457s Year: 2005
Proapoptotic and anti-proliferative effect of the stable plasminogen activator inhibitor type 1 (PAI-1) mutant on the lung cancer and endothelial cells Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009
Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients Source: Annual Congress 2004 - Skeletal muscle in respiratory disease Year: 2004
Urokinase plasminogen activator receptor variants drive distinct phenotypes in the bronchial epithelium Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015
SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor growth and lung metastasis formation probably through the reduction of tumor angiogenesis Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
Plasminogen activator inhibitor (PAI)-1 is expressed in human eosinopils stimulated by TGF-β Source: Eur Respir J 2006; 28: Suppl. 50, 590s Year: 2006
Plasminogen activator inhibitor type 1 (PAI-1) is a negative regulator of lung cancer cells growth due to its anti-proteinase activity Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD Year: 2008
Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010
Urokinase plasminogen activation receptor (uPAR) levels correlate with bronchial epithelial barrier integrity Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases Year: 2014
Vascular endothelial growth factor (VEGF) isoform expression in primary human cultured alveolar epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 84s Year: 2003
Effects of hypoxia on VEGF and VEGF-R expression by human alveolar epithelial (ATII) and human pulmonary microvascular endothelial (HMVEC-l) cells Source: Annual Congress 2008 - Border patrol: the alveolar barrier in lung injury Year: 2008
Caveolin-1 regulation of thrombin signalling in endothelial cells Source: Annual Congress 2009 - Acute lung injury: biological mechanisms Year: 2009
Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma Source: Eur Respir J 2016; 47:1568-1571 Year: 2016